Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model-Reference-Cited by-同舟云学术

Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bernhard Fabian¹,Odedra Rajesh²,Sordello Sylvie²,Cardin Rossella³,Franzoni Samantha³,Charrier Cédric⁴,Belley Adam⁵,Warn Peter²,Machacek Matthias¹,Knechtle Philipp⁵^ORCID

Affiliation:

1. LYO-X GmbH, Allschwil, Switzerland

2. Evotec (UK) Ltd., Cheshire, United Kingdom

3. Aptuit (Verona) Srl, Verona, Italy

4. IHMA Europe Sàrl, Monthey, Switzerland

5. Allecra Therapeutics SAS, Saint-Louis, France

Abstract

Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empirical treatment of serious Gram-negative infections in settings where ESBLs are prevalent. Cefepime-enmetazobactam has been investigated in a phase 3 trial in patients with complicated urinary tract infections or acute pyelonephritis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00078-20

Reference46 articles.

1. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. Past and Present Perspectives on β-Lactamases

4. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program

5. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamics of taniborbactam in combination with cefepime studied in an in vitro model of infection;International Journal of Antimicrobial Agents;2024-10

2. Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates;Journal of Global Antimicrobial Resistance;2024-09

3. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

4. Cefepime/Enmetazobactam: First Approval;Drugs;2024-05-18

5. In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales;Frontiers in Pharmacology;2024-04-11